BioAdaptives, Inc. introduces PrimiSleep™, an advanced solution

PrimiSleep™ enters the rapidly growing global sleep aid market with a state-of-the-art supplement

LAS VEGAS, NV, July 07, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – BioAdaptives, Inc. (OTCMkts: BDPT), is pleased to announce the launch of a new all-natural anti-stress product, PrimiSleep™, specially designed to induce relaxation and continuous restful sleep. Extensively developed and market tested, this advanced formulation is based on traditional Chinese medicine and Ayurvedic culture in response to a growing demand for an effective natural sleep supplement without the commonly associated “hangover” effect. .

An important feature of PrimiSleep™ is that, unlike most pharmaceuticals, there should be no interference with cognitive ability should you wake up unexpectedly or have difficulty in the process of returning to sleep. PrimiSleep™ is specifically formulated with balanced ingredients to replenish energy and vitality. Clinical studies show that the components of PrimiSleep™ promote a restful sleep pattern with increased REM intervals known to be beneficial. PrimiSleep™ is all natural, contains no pharmaceuticals, and has had no reported adverse effects or addiction issues.

According to Center for Disease Control, more than 70 million Americans currently suffer from chronic sleep problems. Published reports estimate that the global market for sleeping pills totaled US$64 billion in 2021 and is expected to reach US$118 billion by 2030, growing at a compound annual growth rate of 7.1%.

Edward Jacobs, MD, CEO of BioAdaptives, says, “The average adult needs about 7-8 hours of sleep a day to stay healthy and productive. The striking increase in sleep-related problems may be due to a variety of factors ranging from coping with more stressful lifestyles in general, to possibly even the emergence of new chronic symptoms such as “long distance” symptoms. felt after COVID 19 infections. We are pleased to meet the growing demand from those seeking help to manage sleep disorders by offering the clinically backed all-natural supplement, PrimiSleep™.

Dr. Jacobs concludes: “We are very encouraged by the positive feedback from consumers who report that using PrimiSleepTM has resulted in gentle pre-bedtime relaxation followed by natural, healthy and continuous sleep. It is known that optimal sleep is widely beneficial to overall health and that sleep disturbances can be even more detrimental by exacerbating other problems such as “brain fog”, depressed mood, fatigue, weakness immunity, obesity, hypertension and diabetes. »

About BioAdaptives, Inc.

BioAdaptives, Inc. manufactures and distributes natural herbal and seaweed products that enhance the health and well-being of humans and animals, with a focus on optimizing pain relief, antiviral activity and defense of the immune system; stress resistance; endurance; recovery from injury, illness and exercise; and anti-aging properties. The company’s current dietary supplement formulations are carefully selected from the best global sources and utilize proprietary methods to enhance nutrient bioavailability. Horse and dog products have also been shown to improve general health, improve competitive performance, rejuvenate effects and relieve pain, and improve appearance. Our current product line includes PrimiLungs™ and PluriPain® for humans and Equine All-in-One™ for horses. Other human products, soon to be introduced, are designed to help memory, cognition and concentration; help reduce sleep and fatigue; and improve overall emotional and physical well-being. Common stock of BioAdaptives trades on the OTC market under the symbol BDPT. It has more than 13,000 current shareholders. None of the Company’s product statements have been approved by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. »

Additional information can be found at or in our filings with the SEC at

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analyzes and other information contained in this press release, including Words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” and similar expressions of opinion constitute forward-looking statements. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from future results described in the forward-looking statements. Risk factors that could contribute to these differences include matters more fully disclosed in the Company’s reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update any forward-looking information in the future. Accordingly, such forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations
BioAdaptives, Inc.
(702) 659-8829
[email protected]

Source link